Europe News

Found 104,306 articles

• Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

  3/23/2023

  Anaveon, a clinical stage, immuno-oncology company, announced that it will present a poster on ANV600 at the American Association for Cancer Research 23rd Annual Meeting being held from Friday, April 14, 2023, to Wednesday, April 19, 2023, in Orlando, Florida.

• Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

  3/23/2023

  Sosei Group Corporation announces the election of Ms. Eiko Tomita to the Board of Directors as an Independent External Director, and the promotion of Ms. Candelle Chong to Executive Vice President and Chief of Staff at the Company’s 33rd Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

• Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

  3/23/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its results for the year ended December 31, 2022 and provided a corporate update.

• Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

  3/23/2023

  POXEL SA announced that is has finalized agreements with its lenders to restructure its existing debt obligations and a new equity-linked financing with IRIS with an initial drawdown of EUR 3.5 million.

• Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

  3/23/2023

  Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.

• Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan

  3/23/2023

  Basilea Pharmaceutica Ltd announced that its license partner Asahi Kasei Pharma has reported the achievement of a milestone related to the launch of Cresemba® in Japan, which triggered a CHF 5 million payment from AKP to Basilea.

• Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial

  3/23/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

• Valneva Reports Full Year 2022 Results and Provides Corporate Updates

  3/23/2023

  Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.

• Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

  3/23/2023

  Macomics Ltd announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.

• Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

  3/22/2023

  Oculis Holding AG announces that it will ring the Nasdaq opening bell to celebrate its public listing on the Nasdaq Stock Market earlier this month.

• Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

  3/22/2023

  Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.

• TC Biopharm Announces Corporate Restructuring, Reduction in Overhead

  3/22/2023

  TC BioPharm PLC announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.

• FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management

  3/22/2023

  The U.S. Food and Drug Administration (FDA) has cleared expanded Indications for Use for screening with FibroScan®, the non-invasive liver management technology by Echosens.

• InflaRx Reports Full Year 2022 Financial and Operating Results

  3/22/2023

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022.

• BioBam Renews KEGG Pathway Licensing for OmicsBox

  3/22/2023

  BioBam, a leading bioinformatics software company, announces the renewal of its KEGG license through a Business Provider Agreement with Pathway Solutions Inc., the exclusive worldwide licensing agent for KEGG resources.

• Guerbet: 2022 annual results

  3/22/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated financial statements for the 2022 fiscal year.

• Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

  3/22/2023

  Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ.

• InvoX Pharma’s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody

  3/22/2023

  InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.

• Poxel will Report its 2022 Full Year Results on March 23, 2023

  3/22/2023

  POXEL SA announced it will report its 2022 Full year results on March 23, 2023, before market opening.

• AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

  3/22/2023

  AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).